Mesothelioma Surgery

Mesothelioma Surgery
Primary Procedures	P/D, EPP, CRS-HIPEC
Preferred Approach (2025)	Pleurectomy/Decortication (P/D)
P/D Operative Mortality	3% at high-volume centers
EPP Operative Mortality	5–7% at high-volume centers
CRS-HIPEC Median Survival	53 months (peritoneal)
Eligible Histology	Epithelioid (primary); biphasic (case-by-case)
MARS 2 Finding	Surgery + chemo did not improve survival over chemo alone
Key Landmark Trials	MARS 1, MARS 2, MesoVATS

Executive Summary

Mesothelioma surgery encompasses several distinct procedures designed to remove cancerous tissue from the pleural or peritoneal lining, ranging from curative-intent operations to palliative interventions that relieve symptoms. The surgical landscape has shifted dramatically over the past two decades. The 2025 NCCN guidelines now recommend pleurectomy/decortication (P/D) over extrapleural pneumonectomy (EPP), limiting surgical consideration to patients with stage I epithelioid disease and no lymph node involvement. A 2025 meta-analysis of 24 studies confirmed that P/D provides approximately 7 months longer median survival than EPP with significantly lower operative mortality.

For peritoneal mesothelioma, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) remains the standard curative-intent treatment. The landmark Yan et al. multicenter study of 405 patients reported a median survival of 53 months with 5-year survival of 47%. Completeness of cytoreduction is the strongest predictor of outcome, with patients achieving CC-0 (no visible residual disease) reaching median survival of 94 months.

The MARS 2 trial — the largest randomized controlled trial of mesothelioma surgery to date — enrolled 335 patients and found that extended P/D plus chemotherapy produced worse overall survival than chemotherapy alone (19.3 vs. 24.8 months). This result has generated significant controversy, with critics citing suboptimal patient selection and unequal immunotherapy access between groups. Despite these debates, surgery remains a treatment option for carefully selected patients at high-volume centers, particularly those with early-stage epithelioid disease and adequate cardiopulmonary reserve.

Mesothelioma patients who have undergone surgery as part of their treatment may be eligible for compensation through asbestos trust fund claims, personal injury lawsuits, or veterans' benefits programs.

At-a-Glance

Mesothelioma surgery at a glance:

• P/D is now the preferred surgical approach — the 2025 NCCN guidelines recommend pleurectomy/decortication over extrapleural pneumonectomy for eligible patients
• P/D median survival: 16 months vs. EPP: 12 months — the Flores series of 663 patients showed P/D also had lower operative mortality (3% vs. 7%)
• MARS 2 trial: surgery did not improve survival — median OS was 19.3 months with surgery vs. 24.8 months with chemotherapy alone in 335 randomized patients
• CRS-HIPEC achieves 53-month median survival — for peritoneal mesothelioma, with 5-year survival of 47% in the largest multicenter study
• Complete cytoreduction (CC-0) yields 94-month median survival — the CC score is the strongest independent predictor of peritoneal mesothelioma surgical outcomes
• Epithelioid histology is essential for surgical benefit — sarcomatoid patients have only 4-month median post-surgical survival vs. 19 months for epithelioid
• High-volume centers have 30% lower 90-day mortality — 10.0% vs. 14.6% at lower-volume facilities in a study of 1,307 patients
• P/D recovery: 7–14 days hospitalization, 4–6 weeks full recovery — lung function typically returns to near-baseline by 3 months with structured rehabilitation
• Fluorescence-guided surgery detects tumors as small as 1 mm — TumorGlow technology identified fluorescent signal in 100% of pleural mesothelioma lesions tested
• Adjuvant chemotherapy begins 4–8 weeks post-surgery — cisplatin/pemetrexed remains the standard first-line regimen for multimodal treatment

Key Facts

Measure	Finding (Source)
P/D vs. EPP Median Survival	16 vs. 12 months — Flores et al., 663 patients, 3 centers
P/D vs. EPP Operative Mortality	3% vs. 7% — Flores et al., 2008
MARS 2 Surgery vs. Chemo Alone	19.3 vs. 24.8 months median OS — 335 patients, 26 UK hospitals, Lancet Respir Med 2024
EPP Sugarbaker Trimodal Results	5-year survival 22% overall, 39% for epithelioid N0 — 120 patients, Sugarbaker 1996
CRS-HIPEC Peritoneal Median Survival	53 months — Yan et al. 2009, 405 patients, multicenter
CC-0 Cytoreduction Median Survival	94 months — Yan et al. analysis of completeness of cytoreduction
Trimodal Therapy Best Subset	59-month median survival — De Perrot 2009, N0 patients completing full protocol
High-Volume vs. Low-Volume Center 90-Day Mortality	10.0% vs. 14.6% — National Cancer Database, 1,307 patients
Sarcomatoid Median Post-Surgical Survival	4 months — SEER data, vs. 19 months for epithelioid
Post-EPP Atrial Fibrillation Rate	21–44% — vs. 7.4% after P/D
Fluorescence-Guided Surgery Detection	100% of MPM lesions, deposits ≥1 mm — TumorGlow clinical trial, University of Pennsylvania

What Are the Main Surgical Options for Pleural Mesothelioma?

Two curative-intent procedures dominate pleural mesothelioma surgery: pleurectomy/decortication (P/D) and extrapleural pneumonectomy (EPP). The choice between them has been one of the most debated questions in thoracic oncology for over two decades.

Pleurectomy/Decortication (P/D)

P/D is a lung-sparing procedure that removes the parietal and visceral pleura while preserving the underlying lung. Three variants exist: partial pleurectomy (palliative), standard P/D (complete pleural resection), and extended P/D (EPD), which adds resection of the pericardium and/or diaphragm.

The landmark 2008 Flores retrospective series compared 663 patients across three US academic centers and found that P/D achieved better median survival than EPP (16 vs. 12 months, p < 0.001), lower operative mortality (3% vs. 7%), and lower distant recurrence rates (35% vs. 66%). Local recurrence was higher with P/D (65% vs. 33%), reflecting the trade-off of preserving lung tissue.

A 2025 meta-analysis of 24 retrospective studies confirmed these findings, showing P/D was associated with approximately 7 months longer overall survival and significantly lower 30-day postoperative mortality compared to EPP. The 2025 NCCN guidelines now formally recommend P/D over EPP.

Extrapleural Pneumonectomy (EPP)

EPP is the most radical mesothelioma surgery, involving en bloc removal of the parietal and visceral pleura, the ipsilateral lung, pericardium, and hemidiaphragm. The diaphragm and pericardium are reconstructed with synthetic mesh patches.

The 1996 Sugarbaker series of 120 consecutive patients at Brigham and Women's Hospital established the trimodal protocol: EPP followed by chemotherapy and hemithoracic radiation. Overall 5-year survival was 22%, but patients with epithelioid histology and negative nodes achieved 5-year survival of 39%. Operative mortality was 5.0%. By comparison, Butchart's initial 1976 series of 29 EPP patients had a 31% hospital mortality rate, illustrating how outcomes improved with surgical refinement.

De Perrot et al. (2009) reported that patients completing the full trimodal protocol with N0 disease achieved a median survival of 59 months and 5-year disease-free survival of 53%. However, only approximately half of patients were able to complete the full protocol.

Despite these results in selected subgroups, the overall trend in mesothelioma surgery has moved decisively toward lung-sparing P/D.

What Did the MARS Trials Reveal About Surgery?

The Mesothelioma and Radical Surgery (MARS) trials are the most important randomized evidence in mesothelioma surgical oncology.

MARS 1 (2011)

The original MARS trial randomized 50 patients to EPP versus no EPP after induction chemotherapy. Results showed no overall survival advantage for EPP, increased risk of death, and poorer quality of life. This trial effectively shifted the surgical paradigm away from EPP.

MARS 2 (2024)

MARS 2 enrolled 335 patients across 26 UK hospitals. After two cycles of platinum-pemetrexed chemotherapy, patients were randomized to extended P/D plus continued chemotherapy or chemotherapy alone. The results were striking:

• Median overall survival was 19.3 months in the surgery group versus 24.8 months in the chemotherapy-alone group (p = 0.019)
• Surgery was associated with a 28% increase in risk of death in the first 42 months (HR 1.28)
• Serious adverse events were 3.6-fold higher in the surgery group (318 vs. 169 events)
• 30-day mortality was 4%; 90-day mortality was 9%
• The effect was dramatically worse for non-epithelioid subtypes (HR 2.66) compared to epithelioid (HR 1.12)

Controversy and Criticism

MARS 2 generated substantial controversy. Critics argue that the 9% 90-day mortality exceeded rates at experienced centers, staging relied on CT without mandatory PET-CT or invasive mediastinal staging, and 34% of surgical patients had T3 disease with 8% having N2 disease — suggesting suboptimal patient selection. The surgery group also received significantly less subsequent immunotherapy (22% vs. 39%).

Many thoracic surgeons maintain that surgery benefits carefully selected patients — those with early-stage epithelioid disease, negative nodes, and adequate performance status — treated at high-volume centers. Ongoing trials such as AtezoMeso and CHIMERA are evaluating surgery combined with immunotherapy.

What Is Cytoreductive Surgery with HIPEC for Peritoneal Mesothelioma?

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is the standard curative-intent treatment for malignant peritoneal mesothelioma. During CRS, the surgeon removes all visible tumor from peritoneal surfaces. The open abdomen is then bathed in heated chemotherapy (typically cisplatin-based) at 41–43°C for 60–120 minutes.

Survival Outcomes

The landmark 2009 Yan et al. multicenter study of 405 patients reported an overall median survival of 53 months, with 3-year and 5-year survival rates of 60% and 47%, respectively.

A large single-center study of 111 patients at the Washington Cancer Institute found that patients surviving to the 1-year mark had conditional median survival of 58.4 months. Patients who underwent a second CRS-HIPEC procedure had median survival of approximately 5.6 years versus 3.0 years for a single procedure.

Peritoneal Cancer Index (PCI) and Completeness of Cytoreduction

The PCI divides the abdomen into 13 regions, scoring each from 0 to 3 based on tumor size, yielding a total from 0 to 39. A PCI threshold of approximately 20 marks the point above which outcomes decline significantly.

The Completeness of Cytoreduction (CC) score is the strongest independent predictor of survival:

CC Score	Residual Tumor	Median Survival
CC-0	No visible disease	94 months
CC-1	Residual ≤2.5 mm	67 months
CC-2	Residual 2.5 mm–2.5 cm	40 months
CC-3	Residual >2.5 cm	12 months

Who Is Eligible for Mesothelioma Surgery?

Surgical candidacy depends on four primary factors: histological subtype, disease stage, performance status, and cardiopulmonary function.

Histological Subtype

Histology is the single most important predictor of surgical benefit. The MARS 2 trial confirmed that surgery had a dramatically worse impact in non-epithelioid patients (HR 2.66) versus a more modest effect in epithelioid patients (HR 1.12). Median post-surgical survival by subtype (SEER data): epithelioid 19 months, biphasic 12 months, sarcomatoid 4 months. Most current protocols exclude sarcomatoid patients from curative-intent surgery.

Stage and Nodal Status

The 2025 NCCN guidelines limit surgical consideration to patients with stage I disease confined to the pleura with no lymph node involvement. Pre-operative evaluation should include contrast-enhanced CT, PET-CT, and consideration of mediastinal staging.

Performance Status

Patients must have an ECOG performance status of 0 or 1 for curative-intent surgery. In peritoneal disease, ECOG 3 status was independently associated with dramatically higher postoperative mortality (HR 13.3, p < 0.001).

Cardiopulmonary Reserve

EPP removes an entire lung, requiring sufficient cardiac and respiratory function. In the MARS 2 cohort, mean FEV1 was approximately 75% predicted, mean FVC approximately 78% predicted, and mean TLCO approximately 74–78% predicted.

What Are the Palliative Surgical Procedures?

Not all mesothelioma patients are candidates for curative-intent surgery. Palliative procedures focus on relieving symptoms and improving quality of life.

Pleurodesis

Pleurodesis obliterates the pleural space to prevent recurrent malignant pleural effusion. Sterile talc is instilled into the pleural space to create adhesion between the visceral and parietal pleura. The MesoVATS trial compared VATS partial pleurectomy to talc pleurodesis in 175 patients and found no survival advantage for surgery. Pleurodesis failure occurs in approximately 22.5% of cases.

Indwelling Pleural Catheter (IPC)

IPCs allow patients to drain pleural fluid at home on a scheduled basis. A randomized trial of 146 patients showed IPC significantly reduced lifetime hospitalization days compared to talc pleurodesis (10 vs. 12 days), with fewer patients requiring further procedures (4% vs. 22.5%). IPCs can induce spontaneous pleurodesis over time, potentially allowing catheter removal.

Pericardial Window

For patients with pericardial effusion, a pericardial window creates a surgical opening to drain fluid. Surgical pericardial window has a significantly lower recurrence rate compared to pericardiocentesis alone (0% vs. 34%).

What Does Recovery from Mesothelioma Surgery Look Like?

Recovery timelines vary significantly by procedure type.

P/D Recovery

After P/D, patients typically spend 1–3 days in the ICU followed by 7–14 days total hospitalization. Chest tubes remain for 10–12 days to manage air leaks from the denuded lung surface. Full recovery takes 4–6 weeks. Breathing exercises begin within 48 hours, and structured pulmonary rehabilitation has demonstrated 93% adherence at 1 month with improvements in physical function and pain scores.

Most patients (85–90%) go home directly from the hospital. Patients are instructed to walk 20 minutes daily and avoid lifting more than 10 pounds for 6–8 weeks. Lung function typically recovers to near-baseline by 3 months with structured rehabilitation.

EPP Recovery

EPP recovery is more extensive: 2 weeks hospitalization with ICU stays of several days, and 6–8 weeks to 4 months for full recovery. Atrial fibrillation occurs in 21–44% of post-EPP patients. The remaining lung must compensate for the entire respiratory workload, and patients face permanent activity limitations due to single-lung physiology.

CRS-HIPEC Recovery

Hospital stays for CRS-HIPEC range from 8 to 22 days. Total recovery takes approximately 3 months. The GI tract requires careful dietary progression: IV nutrition for days 1–3, clear liquids by days 3–5, gradual progression to solid foods over 2–4 weeks. Some patients require temporary stoma creation if bowel resection is performed.

Adjuvant Treatment Timing

Adjuvant chemotherapy typically begins 4–8 weeks post-surgery. The standard first-line regimen is cisplatin/pemetrexed. Delayed initiation (2–3 months) in older patients or those with slower recovery still confers benefit.

How Does Surgeon Volume Affect Outcomes?

A study of 1,307 patients from the National Cancer Database found that high-volume facilities had significantly better outcomes than lower-volume centers:

• Lower 30-day readmission rates: 4.6% vs. 6.1% (p = 0.021)
• Lower 90-day mortality: 10.0% vs. 14.6% (p = 0.029)
• Shorter postoperative hospitalization (p = 0.035)

The ERS/ESTS/EACTS/ESTRO 2020 European guidelines explicitly recommend that radical surgery should only be performed at high-volume centers, in clinical trials, and as part of multimodal treatment. The International Association for the Study of Lung Cancer (IASLC) defines low volume as fewer than five radical mesothelioma procedures per year.

Patients should seek treatment at academic institutions with dedicated mesothelioma multidisciplinary teams that include thoracic surgeons, medical oncologists, radiation oncologists, pulmonologists, and pathologists experienced in mesothelioma.

What Emerging Techniques Are Improving Mesothelioma Surgery?

Several technologies are advancing the precision of mesothelioma surgery.

Fluorescence-Guided Surgery

Fluorescence-guided surgery uses optical contrast agents that accumulate in tumor tissue, enabling real-time identification of residual disease during the operation. A clinical trial of TumorGlow technology at the University of Pennsylvania detected fluorescent signal in 100% of pleural mesothelioma lesions, identifying deposits as small as 1 mm. Results were reproducible even after neoadjuvant chemotherapy.

Intraoperative Photodynamic Therapy (PDT)

PDT uses a photosensitizing agent taken up by tumor cells, followed by intraoperative light activation to destroy residual microscopic disease. Friedberg et al. reported that extended P/D combined with PDT yielded nearly 3-year median survival for epithelial-subtype patients. Multiple phase I/II trials are evaluating PDT combined with immunotherapy.

Hyperthermic Intrathoracic Chemotherapy (HITHOC)

Analogous to HIPEC for peritoneal disease, HITHOC perfuses the thoracic cavity with heated chemotherapy after P/D. A 20-year study found that extended P/D with HITHOC and adjuvant chemotherapy yielded median overall survival of 38.1 months.

Minimally Invasive VATS P/D

Video-assisted thoracoscopic P/D is emerging as a feasible alternative for higher-risk patients. An analysis comparing 115 VATS-P/D patients to 269 open P/D patients found improved short-term outcomes with the minimally invasive approach.

What Are the Legal Implications of Mesothelioma Surgery?

Mesothelioma is caused by asbestos exposure, and patients who require surgery may be entitled to significant compensation.

Surgical Costs and Financial Burden

Mesothelioma surgery is among the most complex and costly oncological procedures. EPP and extended P/D require specialized surgical teams, prolonged hospital stays, and extensive post-operative care. The financial burden extends beyond the procedure itself to include rehabilitation, adjuvant chemotherapy, radiation therapy, follow-up imaging, and lost wages during recovery.

Compensation Options

Patients diagnosed with mesothelioma have several legal avenues for recovering costs associated with their treatment:

• Asbestos trust fund claims — over 60 trusts have been established by bankrupt asbestos companies, with billions in assets available for qualified claimants
• Personal injury lawsuits — filed against manufacturers, employers, or property owners who failed to protect workers from asbestos exposure
• Veterans' benefits — military service members exposed to asbestos during service may qualify for VA disability compensation and healthcare benefits
• Workers' compensation — available in some jurisdictions for occupational asbestos exposure

Statute of Limitations

Asbestos claims are subject to statutes of limitations that vary by state and begin running from the date of diagnosis. Because mesothelioma has a latency period of 20–50 years, many states have special provisions for asbestos-related claims. Patients should consult with experienced mesothelioma attorneys promptly after diagnosis to preserve their legal rights.

Frequently Asked Questions

What is the most common mesothelioma surgery?

Pleurectomy/decortication (P/D) is the most commonly performed curative-intent surgery for pleural mesothelioma. The 2025 NCCN guidelines recommend P/D over EPP because it preserves the lung, has lower operative mortality (3% vs. 7%), and provides comparable or superior median survival.

Is mesothelioma surgery worth it?

Surgery can extend survival for carefully selected patients — particularly those with early-stage epithelioid pleural mesothelioma or peritoneal mesothelioma eligible for CRS-HIPEC. The MARS 2 trial found that surgery did not improve overall survival compared to chemotherapy alone in its study population, but many experts argue this reflected suboptimal patient selection rather than surgery itself being ineffective. Patients with peritoneal mesothelioma who achieve complete cytoreduction (CC-0) during CRS-HIPEC reach median survival of 94 months.

How long does it take to recover from mesothelioma surgery?

Recovery varies by procedure: P/D requires 7–14 days hospitalization and 4–6 weeks for full recovery; EPP requires about 2 weeks hospitalization and 6–8 weeks to 4 months for full recovery; CRS-HIPEC requires 8–22 days hospitalization and approximately 3 months total recovery.

What is the survival rate after mesothelioma surgery?

Survival depends on procedure, histology, and disease stage. For pleural mesothelioma, P/D achieves approximately 16-month median survival. For peritoneal mesothelioma, CRS-HIPEC achieves 53-month median survival overall, with CC-0 patients reaching 94 months. Patients with epithelioid histology, negative nodes, and early-stage disease have the best outcomes.

Who qualifies for CRS-HIPEC?

Candidates for CRS-HIPEC typically have peritoneal mesothelioma with a PCI score below 20, ECOG performance status of 0 or 1, epithelioid or biphasic histology, and adequate organ function. The goal is to achieve complete cytoreduction (CC-0 or CC-1), as incomplete cytoreduction is associated with significantly shorter survival.

Can mesothelioma patients sue for surgical costs?

Mesothelioma patients may recover compensation for surgical costs and related expenses through asbestos trust fund claims, personal injury lawsuits, veterans' benefits, or workers' compensation. Over 60 asbestos trust funds hold billions in assets for qualified claimants. An experienced mesothelioma attorney can evaluate which compensation pathways apply to a specific case.

What is the difference between EPP and P/D?

EPP removes the entire lung along with the pleura, pericardium, and diaphragm. P/D removes only the pleural lining while preserving the lung. P/D has lower operative mortality (3% vs. 7%), better median survival (16 vs. 12 months), and fewer permanent activity limitations. The 2025 NCCN guidelines recommend P/D over EPP.

What is the MARS 2 trial?

MARS 2 is the largest randomized controlled trial of mesothelioma surgery, published in The Lancet Respiratory Medicine in 2024. It enrolled 335 patients across 26 UK hospitals and found that extended P/D plus chemotherapy produced worse median overall survival than chemotherapy alone (19.3 vs. 24.8 months). The trial remains controversial, with critics citing suboptimal patient selection and unequal access to subsequent immunotherapy between groups.

Quick Statistics

• P/D operative mortality: 3% at high-volume centers
• EPP operative mortality: 5–7% at high-volume centers
• P/D median survival: 16 months (Flores series, 663 patients)
• CRS-HIPEC median survival: 53 months (Yan et al., 405 peritoneal patients)
• CC-0 cytoreduction survival: 94 months median (peritoneal mesothelioma)
• Trimodal therapy best subset: 59-month median survival (N0 patients)
• Post-EPP atrial fibrillation: 21–44% of patients
• High-volume center 90-day mortality: 10.0% vs. 14.6% at low-volume
• P/D hospital stay: 7–14 days; full recovery 4–6 weeks
• MARS 2 result: Surgery did not improve survival over chemotherapy alone

Get Help

If you or a loved one has been diagnosed with mesothelioma and is considering surgery, experienced attorneys can help you understand your legal options while you focus on treatment.

• Free case evaluation: Contact Danziger & De Llano for a no-obligation consultation
• Treatment information: Mesothelioma Treatment Options
• Asbestos trust fund claims: Trust Fund Filing Information

Free, Confidential Case Evaluation Call (866) 222-9990 or visit dandell.com/contact-us No upfront fees • Experienced representation • National practice

⚠ Statute of Limitations Warning: Filing deadlines vary by state from 1-6 years from diagnosis. Texas allows 2 years from diagnosis or discovery. Contact an attorney immediately to preserve your rights.

Related Pages

• Mesothelioma Diagnosis
• Pleural Mesothelioma
• Peritoneal Mesothelioma
• Asbestos Trust Funds
• Survival Statistics
• Shipyard Asbestos Exposure